Urology
Volume 75, Issue 6 , Pages 1249-1253 , June 2010

Phenotypically Directed Multimodal Therapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Study Using UPOINT

References 

  1. Walz J, Perrotte P, Hutterer G, et al. Impact of chronic prostatitis-like symptoms on the quality of life in a large group of men. BJU Int. 2007;100:1307–1311
  2. Shoskes DA, Katz E. Multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2005;6:296–299
  3. Schaeffer AJ. Clinical practice (Chronic prostatitis and the chronic pelvic pain syndrome). N Engl J Med. 2006;355:1690–1698
  4. Shoskes DA, Nickel JC, Rackley RR, et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis. 2009;12:177–183
  5. Shoskes DA, Nickel JC, Dolinga R, et al. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology. 2009;73:538–542
  6. Nickel JC, Shoskes D, Irvine-Bird K. Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management. J Urol. 2009;182:155–160
  7. Hedelin HH. Evaluation of a modification of the UPOINT clinical phenotype system for the chronic pelvic pain syndrome. Scand J Urol Nephrol. 2009;43:373–376
  8. Litwin MS, McNaughton-Collins M, Fowler FJJ, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure (Chronic Prostatitis Collaborative Research Network). J Urol. 1999;162:369–375
  9. Propert KJ, Litwin MS, Wang Y, et al. Responsiveness of the National Institutes of Health chronic prostatitis symptom index (NIH-CPSI). Qual Life Res. 2006;15:299–305
  10. Shoskes DA, Zeitlin SI, Shahed A, et al. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999;54:960–963
  11. Nickel JC, Krieger JN, McNaughton-Collins M, et al. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med. 2008;359:2663–2673
  12. Pranikoff K, Constantino G. The use of amitriptyline in patients with urinary frequency and pain. Urology. 1998;51:179–181
  13. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122:S22–S32
  14. Anderson RU, Sawyer T, Wise D, et al. Painful myofascial trigger points and pain sites in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol. 2009;182:2753–2758
  15. Shoskes DA, Hakim L, Ghoniem G, et al. Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. J Urol. 2003;169:1406–1410
  16. Nickel JC. Role of alpha1-blockers in chronic prostatitis syndromes. BJU Int. 2008;101(Suppl 3):11–16
  17. Alexander RB, Propert KJ, Schaeffer AJ, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med. 2004;141:581–589
  18. Pontari MA, McNaughton-Collins M, O'Leary MP, et al. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int. 2005;96:559–565
  19. Nickel JC, Tripp DA, Chuai S, et al. Psychosocial variables affect the quality of life of men diagnosed with chronic prostatitis/chronic pelvic pain syndrome. BJU Int. 2008;101:59–64
  20. Shoskes DA, Berger R, Elmi A, et al. Muscle tenderness in men with chronic prostatitis/chronic pelvic pain syndrome: the chronic prostatitis cohort study. J Urol. 2008;179:556–560
  21. Schaeffer AJ, Landis JR, Knauss JS, et al. Demographic and clinical characteristics of men with chronic prostatitis: the National Institutes of Health chronic prostatitis cohort study. J Urol. 2002;168:593–598
  22. Nickel JC, Downey J, Pontari MA, et al. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int. 2004;93:991–995
  23. Wagenlehner FM, Schneider H, Ludwig M, et al. A pollen extract (cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56:544–551
  24. Shahed AR, Shoskes DA. Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. J Urol. 2001;166:1738–1741
  25. Shahed AR, Jones E, Shoskes D. Quercetin and curcumin up-regulate antioxidant gene expression in rat kidney after ureteral obstruction or ischemia/reperfusion injury. Transplant Proc. 2001;33:2988–2989
  26. Wan LL, Xia J, Ye D, et al. Effects of quercetin on gene and protein expression of NOX and NOS after myocardial ischemia and reperfusion in rabbit. Cardiovasc Ther. 2009;27:28–33
  27. Geoghegan F, Wong RW, Rabie AB. Inhibitory effect of quercetin on periodontal pathogens in vitro. Phytother Res. 2009;epub ahead of print
  28. Ozcelik B, Orhan I, Toker G. Antiviral and antimicrobial assessment of some selected flavonoids. Z Naturforsch C. 2006;61:632–638

PII: S0090-4295(10)00094-4

doi: 10.1016/j.urology.2010.01.021

Urology
Volume 75, Issue 6 , Pages 1249-1253 , June 2010

Article Tools

* Image Usage & Resolution